As with the other markets examined in this forecast, dyslipidemia sales in the 5EU in the 2013 base
year were dominated by the statins and ezetimibe. In 2013, statin sales contributed 64% ($1.5
billion) towards the dyslipidemia market share in the 5EU.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the
purchase.
Scope
- Overview of Dyslipidemia i0ncluding epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Dyslipidemia
market.
Request a Sample Copy of This Report @
http://www.radiantinsights.com/research/dyslipidemia-5eu-drug-forecast-and-market-
analysis-to-2023/request-sample
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
Dyslipidemia.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.
See More Reports of This Category by Radiant Insights @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Follow Us: